NANOG and hepatocellular carcinoma: Additionally, NANOG inhibitors BBI608 or BBI503 were combined with sorafenib in adult patients with hepatocellular carcinoma in a phase II study (NCT02279719).31 Promising antitumor effects have been observed in patients with hepatocellular carcinoma who have not undergone systemic chemotherapy previously, and the trial was completed in 2002.